AEterna Zentaris Inc. (AEZS)

NASDAQ: AEZS · IEX Real-Time Price · USD
3.85
-0.02 (-0.52%)
Dec 9, 2022 3:51 PM EST - Market closed
-0.52%
Market Cap 18.93M
Revenue (ttm) 6.63M
Net Income (ttm) -13.46M
Shares Out 4.86M
EPS (ttm) -0.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 38,789
Open 3.75
Previous Close 3.87
Day's Range 3.75 - 4
52-Week Range 3.51 - 11.5
Beta 1.64
Analysts Buy
Price Target n/a
Earnings Date Nov 3, 2022

About AEZS

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license ag... [Read more]

Industry Biotechnology
IPO Date Jul 18, 1996
CEO Klaus Paulini
Employees 11
Stock Exchange NASDAQ
Ticker Symbol AEZS
Full Company Profile

Financial Performance

In 2021, AEZS's revenue was $5.26 million, an increase of 44.03% compared to the previous year's $3.65 million. Losses were -$8.37 million, 63.5% more than in 2020.

Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target
n/a
Analyst Consensus: Buy
Stock Forecasts

News

Aeterna Zentaris (AEZS) Reports Q3 Loss, Tops Revenue Estimates

Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of -2.94% and 38.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Aeterna Zentaris Reports Third Quarter 2022 Financial Results

– Company ended the quarter with $ 53.8 million in cash

1 month ago - GlobeNewsWire

Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk

– Company plans to prioritize efforts to identify new strategic development and commercialization partner

3 months ago - GlobeNewsWire

Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights

– Company ended the quarter with $58.2 million in cash

4 months ago - GlobeNewsWire

Aeterna Zentaris Announces Effective Date of Share Consolidation

TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therape...

4 months ago - GlobeNewsWire

Aeterna Zentaris Announces Shareholder Approval of Share Consolidation

TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a ...

4 months ago - GlobeNewsWire

Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting

TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a ...

5 months ago - GlobeNewsWire

Aeterna Zentaris Announces Results of Annual Meeting of Shareholders

- Vote to approve share consolidation adjourned to July 6, 2022

5 months ago - GlobeNewsWire

Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference

TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a d...

6 months ago - GlobeNewsWire

Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parki...

– Data presented at IMMUNOLOGY2022 ™ , the A nnual Event of the American Association of Immunologists

6 months ago - GlobeNewsWire

Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook

– C ontinue d advancement across di versified development pipeline

6 months ago - GlobeNewsWire

Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association ...

– Company advancing development of its Autoimmunity Modifying AIM Biologic al s as a potential therapeutic treatment option for Parkinson's Disease (" PD "), a neurodegenerative movement disorder

7 months ago - GlobeNewsWire

Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Defici...

– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin ® / Macrilen ™ in Europe as the Company plans to pursue even greater protection

7 months ago - GlobeNewsWire

JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ:...

- Live video webcast events on Thursday, April 14 at 10 AM ET, 11:30 AM ET and 1 PM ET - FRENCHTOWN, NJ / ACCESSWIRE / April 13, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and ...

Other symbols: ARECCNSP
7 months ago - Accesswire

Aeterna Zentaris to Participate at the Virtual Investor 2022 CEO Spotlight

– Live moderated video webcast fireside chat with Dr. Klaus Paulini , CEO and Giuliano La Fratta, CFO of Aeterna Zentaris, on Thursday , April 14th at 10 :00 AM ET

7 months ago - GlobeNewsWire

Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity

– Company to present regarding AIM Biologic al s as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD"), an orphan indication with strong unmet medical need

7 months ago - GlobeNewsWire

Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth ...

– Company actively monitoring delays to mitigate potential impact of COVID-19 and conflict in Ukraine following Russian invasion on the estimated completion dates for the trial

8 months ago - GlobeNewsWire

Aeterna Zentaris Announces Expansion of Research Program with Julius-Maximilians-University Wuerzburg Aiming to Accel...

– R esearch agreement expanded for development of human 3D intestinal tissue models to study Salmonella enterica pathogenesis

8 months ago - GlobeNewsWire

Aeterna Zentaris Announces Notice of Allowance for U.S. Patent Covering AEZS-150 for the Potential Treatment of Chron...

– Notice of allowance received by Company's l icensor, The University of Sheffield (UK) bolsters intellectual property of AEZS-150 in development for the potential treatment of chronic hypoparathyroidism –

9 months ago - GlobeNewsWire

Aeterna Zentaris to Present at the 2022 BIO CEO & Investor Conference

CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a ...

10 months ago - GlobeNewsWire

Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

CHARLESTON, S.C., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a ...

10 months ago - GlobeNewsWire

Aeterna Zentaris Provides Business Outlook and Outlines Pipeline Priorities

– Company advancing diversified portfolio focused on areas of significant unmet medical need – Supported by solid financial position with cash to fund operations beyond 2023

10 months ago - GlobeNewsWire

Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference

– Live video webcast presentation on Wednesday, January 26 th at 9:00 AM ET

10 months ago - GlobeNewsWire

Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference

CHARLESTON, S.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a ...

11 months ago - GlobeNewsWire

Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer

– Well-established finance professional with over 20 years of experience gained in pharmaceutical, biopharma and professional services sectors

11 months ago - GlobeNewsWire